The Vanguard Group filed Amendment No. 8 to a Schedule 13G/A for Cigna Group common stock stating it beneficially owns 0 shares, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 that disaggregated certain subsidiaries' holdings and directs those subsidiaries to report separately “in accordance with SEC Release No. 34-39538 (January 12, 1998).” The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
The Cigna Group is seeking shareholder votes at its 2026 virtual annual meeting on April 22, 2026, including electing 12 directors, approving executive pay, ratifying PricewaterhouseCoopers and considering a shareholder written-consent proposal.
For 2025, Cigna reports revenue of $275 billion, up 11%, shareholders’ net income of $6 billion ($22.18 per share), adjusted income from operations of $8 billion ($29.84 per share), operating cash flow of $9.6 billion and $5.2 billion returned via dividends and buybacks. The company invested $3.5 billion in Shields Health Solutions and completed a $4.9 billion sale of Medicare-related businesses, sharpening focus on higher‑growth health services. The proxy also details a planned CEO transition from David Cordani to Brian Evanko on July 1, 2026, an Executive Chair role for Cordani, a strengthened Lead Independent Director role, and extensive governance, sustainability and pay‑for‑performance practices.
Cigna Group disclosed that The Vanguard Group filed an amendment to its Schedule 13G reporting beneficial ownership of 26,445,689 shares of common stock, representing 10.03% of the class.
The filing shows shared voting power of 2,785,837 shares and shared dispositive power over 26,445,689 shares. The filer notes an internal realignment effective January 12, 2026 that will lead certain Vanguard subsidiaries to report beneficial ownership separately.
Cigna Group Chief Accounting Officer Jamie G. Kates reported equity compensation changes. On February 27, 2026, Kates was granted 657 employee stock options and additional shares of common stock as part of strategic performance share settlements and new restricted share awards. The options and restricted shares vest in three equal annual installments beginning March 1, 2027. A total of 71 and 61 shares of common stock were withheld to satisfy tax obligations tied to these awards, leaving Kates with 2,368 common shares directly owned.
Cigna Group executive Durga Prasad Koka reported new equity awards and related tax share withholdings. On February 27, 2026, he was granted an employee stock option for 4,127 shares at a price of $0.00 per share, which vests in three equal annual installments beginning March 1, 2027. He also acquired common stock through settlement of strategic performance shares for the 2023–2025 period and through restricted share grants, with vesting for certain restricted shares also starting March 1, 2027. Separate transactions show small blocks of common stock withheld at $287.55 per share to cover tax obligations on these equity awards, rather than open-market sales.
Cigna Group executive Neville Everett reported several equity transactions involving company stock. On March 2, he completed an open-market sale of 1,719 common shares at a price of $288.91 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2025.
On February 27, he received equity awards tied to company performance and compensation programs, including 2,602 and 2,678 common shares granted at no cost and 4,127 employee stock options that vest in three equal annual installments beginning March 1, 2027. Some common shares (883 and 517) were withheld to cover tax obligations upon settlement of strategic performance shares and vesting of restricted shares.
Cigna Group executive Nicole S. Jones reported a mix of stock transactions. She sold 2,307 shares of common stock at $288.91 per share in an open-market sale executed under a Rule 10b5-1 trading plan adopted on May 8, 2025.
Earlier on February 27, 2026, she received 8,066 employee stock options and 9,367 shares of common stock through equity awards and performance share settlement at no cash cost. On the same date, 2,738 shares were withheld to cover tax obligations tied to those awards.
After these transactions, she directly held 32,647 shares of Cigna common stock and 8,066 stock options, and indirectly held 1,434.7897 shares through participation in The Cigna Group’s 401(k) Plan.
Cigna Group executive Brian C. Evanko reported multiple equity compensation transactions. He received an employee stock option for 15,082 shares and two grants of common stock for 6,428 and 9,787 shares on February 27, 2026, tied to strategic performance shares and restricted stock awards.
The filing also shows dispositions of 2,979 and 1,788 common shares at $287.55 per share, which were withheld to satisfy tax obligations rather than open-market sales. Evanko additionally reports indirect holdings of common stock through a grantor retained annuity trust and The Cigna Group’s 401(k) plan.
Cigna Group EVP and CFO Ann M. Dennison reported equity compensation changes involving company stock. She received an award of 8,066 employee stock options with an exercise price of $0.0000, which vest in three equal annual installments beginning on March 1, 2027. She was also granted 5,234 shares of common stock as restricted shares that vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations upon the vesting of restricted shares, 409 shares of common stock were disposed of at $287.55 per share through share withholding, leaving her with 7,745 common shares held directly.